Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy — TANGO

Uncontrolled Asthma Clinical Trial

Official title:
A 52-week, Randomised, Double Blind, Multicentre, 2-arm Parallel Group Trial Assessing Efficacy of CHF6001 (Total Daily Dose 3200μg) Dry Powder Inhaler (DPI) add-on to Maintenance Medium or High Dose of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists in Subjects With Uncontrolled Asthma

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of CHF6001 (Tanimilast) as add-on to maintenance of inhaled corticosteroids in combination with Long-acting ß2-agonists in the target patient population. (TANGO)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06029595
Study type	Interventional
Source	Chiesi Farmaceutici S.p.A.
Contact	Chiesi Clinical Trial info
Phone	+3905212791
Email	clinicaltrials_info@chiesi.Com
Status	Recruiting
Phase	Phase 2
Start date	November 26, 2023
Completion date	December 18, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02194699` - A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma	Phase 3
Active, not recruiting	`NCT03978936` - Medication Adherence With Telehealthcare Medication Therapy Management	N/A
Completed	`NCT02161757` - A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma	Phase 3
Completed	`NCT02768623` - Evaluation of a Community Pharmacist Managed Asthma Consultation Service	N/A
Completed	`NCT02906761` - Aspirin for Uncontrolled Asthma	Phase 3
Completed	`NCT04865575` - Systems Pharmacology Approach to Uncontrolled Pediatric Asthma